Manner of Payment. All payments owed by one Party to the other Party under Sections 5.3, 5.4, and 5.5 shall be offset against the payments owned by the other Party to the first Party. The net payments thus owed shall be paid by wire transfer to a bank account designated by the applicable payee Party. All net payments owed under Sections 5.3, 5.4, and 5.5 shall be paid on a ​ basis, with such payment being made for the prior ​ no later than ​ after the end of such prior ​ in which such amounts could be calculated. Notwithstanding the foregoing, if for any ​ the reimbursable costs exceed the recognized Net Sales for such ​, then each party shall be reimbursed from the recognized Net Sales for such ​ at a rate of ​ to Evoke and ​ to Eversana. To the extent one of the Parties has been fully reimbursed for such ​, then any remaining Net Sales amount from such ​ would be paid to the other Party until the Net Sales amount from such ​ has been exhausted. For clarity, Evoke shall have no obligation to reimburse Commercialization Costs except in the manner described in this Section 5.6.

“All payments owed by one Party to the other Party under [Sections 5.3, 5.4, and 5.5]5]5] shall be offset against the payments owed by the other Party to the first Party. The net payments thus owed shall be paid by wire transfer to a bank account designated by the applicable payee Party. All net payments owed under [Sections 5.3, 5.4, and 5.5]5]5] shall be paid on a ​ basis, with such payment being made for the ​ no later than ​ after the end of ​ in which such amounts could be calculated. Notwithstanding the foregoing, if for any ​ the reimbursable costs under [Sections 5.3 and 5.4]4] exceed the recognized Net Sales for ​, then each party shall be reimbursed from the recognized Net Sales for ​ at a rate of ​ of each Net Sales dollar to Evoke and ​ of each Net Sales dollar to Eversana. To the extent one of the Parties has been fully reimbursed for its reimbursable costs under [Sections 5.3 and 5.4]4] for ​, then any remaining Net Sales from ​ would be paid to the other Party until the Net Sales from ​ have been exhausted. If one of the Parties has not been fully reimbursed for its reimbursable costs under [Sections 5.3 and 5.4in]n] one or more of the ​ on an aggregate basis (“Cumulative Deferred Costs”) and there remains recognized Net Sales from ​ in excess of the reimbursable amounts for ​, then up to ​ of the excess from ​ shall be used to reimburse such Party’s Cumulative Deferred Costs and [Section 5.5] shall apply to the remainder of any such excess. For clarity, during the Term, Evoke shall have no obligation to reimburse Commercialization Costs except in the manner described in this [Section 5.6].” (c) [Section 14.1] of the CSA is hereby deleted in its entirety and replaced with the following: